Recor Medical, a subsidiary of Otsuka Medical Devices, has achieved a significant milestone with the approval of its Paradise Ultrasound Renal Denervation (uRDN) system in Japan for the treatment of resistant hypertension. This groundbreaking technology represents the first medical device in Japan specifically designed to address hypertension, offering a new approach to managing this challenging condition.
The Paradise uRDN system utilizes innovative ultrasound-based technology to target and denervate the sympathetic nerves surrounding the renal arteries. By reducing the overactivity of these nerves, which can contribute to hypertension, the system aims to lower blood pressure effectively. Through the delivery of controlled doses of 360-degree ultrasound energy to the renal artery nerves, the Paradise catheter, equipped with the HydroCooling™ system, ensures the safety of the procedure by protecting the renal arterial wall.
The approval in Japan follows the successful outcomes of the RADIANCE-HTN TRIO study conducted in the U.S. and Europe. This randomized clinical trial, which compared the Paradise uRDN system to a sham procedure in patients with resistant hypertension, demonstrated a significant reduction in systolic blood pressure two months post-treatment. Importantly, the system showed a favorable safety profile throughout the study, highlighting its potential as a safe and effective treatment option.
Resistant hypertension poses a significant health risk, often remaining uncontrolled despite traditional medication. With the introduction of the Paradise uRDN system in Japan, patients now have access to a novel therapeutic approach that has the potential to improve blood pressure management and reduce the associated risks of cardiovascular diseases. This approval signifies a major advancement in the field of cardiovascular care and underscores the commitment to providing innovative solutions for patients in need.
The collaborative efforts of prominent academic societies in Japan, including the Japanese Society of Hypertension, the Japanese Circulation Society, and the Japanese Association of Cardiovascular Intervention and Therapeutics, highlight the importance of raising awareness about hypertension and expanding treatment options. By endorsing the Paradise uRDN system, these societies aim to ensure that patients receive appropriate care and have access to cutting-edge treatments for hypertension, a leading cause of cardiovascular events in Japan.
Recor Medical’s commitment to advancing hypertension management is further exemplified by the global success of the Paradise uRDN system. With approvals from the FDA in the U.S. and the CE mark in Europe, along with ongoing post-market studies and registries, the system has demonstrated its effectiveness and safety across different regions. The initiation of a post-marketing surveillance study in Japan underscores the company’s dedication to monitoring the long-term outcomes and safety of the device in real-world clinical settings.
In conclusion, the approval of the Paradise Ultrasound Renal Denervation system in Japan marks a significant milestone in the treatment of resistant hypertension. By introducing a novel and effective approach to managing blood pressure, Recor Medical is poised to revolutionize hypertension care in Japan and globally. Through collaborations with key stakeholders and ongoing research initiatives, the company remains at the forefront of cardiovascular innovation, aiming to improve patient outcomes and reduce the burden of cardiovascular diseases worldwide.
- The Paradise uRDN system offers a groundbreaking approach to treating resistant hypertension by denervating sympathetic nerves around the renal arteries.
- The successful outcomes of the RADIANCE-HTN TRIO study supported the approval of the Paradise uRDN system in Japan, highlighting its efficacy and safety profile.
- Collaborative efforts between academic societies in Japan aim to raise awareness about hypertension and provide innovative treatment options for patients in need.
- Recor Medical’s global success with the Paradise uRDN system, including approvals in the U.S. and Europe, underscores its commitment to advancing hypertension management and improving patient care.
Tags: regulatory
Read more on manilatimes.net